Goal of this study

to treat Alzheimer’s disease.


Alzheimer’s disease is a brain disease that gradually destroys memory and thinking skills. This study will investigate the efficacy of a drug named Solanezumab in slowing down disease progression in patients with very early Alzheimer’s disease (known as prodromal stage of Alzheimer’s disease). This study will also investigate the safety of Solanezumab. Solanezumab will be given to the patient once every four weeks through intravenous infusion for up to two years. Intravenous infusion refers to infusing the drug directly into a vein.

Who can participate in this study?

Patients who have been diagnosed with Alzheimer’s disease at a very early stage (prodromal stage) or with mild cognitive impairment due to Alzheimer’s disease and who are between the ages of 55 and 85 may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT02760602

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.